APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION
The key component of the pathogenesis of pulmonary hypertension (PH) is endothelial dysfunction with imbalance between vasodilators and vasoconstrictors and activation of the blood coagulation system. Randomized trials showed a beneficial effect of phosphodiesterase type 5 (PDE-5) inhibitors on vasc...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2015-06-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/5633 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|